Diabetes can be a co-morbidity that increases risk for which jaw condition?

• A. MRONJ
• B. Osteoradionecrosis
• C. Osteomyelitis
• D. Ameloblastoma

Answer: (A)

The main idea here is how a systemic health issue can interact with jaw-bone–affecting meds to raise the risk of a specific jaw problem. Diabetes contributes to poorer wound healing and impaired immune function, and it can worsen microvascular health. When someone is on antiresorptive medications (like bisphosphonates or denosumab), these drugs already suppress bone turnover and healing. Put together, diabetes makes the jaw more susceptible to necrosis in this drug context, so medication-related osteonecrosis of the jaw becomes more likely.

Osteoradionecrosis requires prior radiation to the jaw, so diabetes isn’t the primary driver there. Osteomyelitis can occur with diabetes due to infection, but the question emphasizes the relation between diabetes as a comorbidity and a jaw condition tied to specific medications, which is MRONJ. Ameloblastoma is a benign tumor unrelated to diabetes or antiresorptive therapy.